Effect of some monoamine oxidase inhibitors on the thiamin status of rabbits

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The monamine oxidase (MAO) inhibitors harmaline, tranylcypromine, deprenyl, clorgyline and iproniazid were injected intraperitoneally for five days to rabbits at doses that produced significant MAO inhibition. The first three inhibitors raised the concentrations of pyruvate and lactate in blood, decreased the activity of erythrocyte transketolase (TK) and increased the thiamin pyrophosphate (TPP) effect. The drugs also produced anorexia and loss of body weight. The changes were suggestive of an adverse effect on the thiamin status. Clorgyline and iproniazid, however, raised the blood concentrations of pyruvate and lactate but did not affect significantly erythrocyte TK activity or TPP effect. Treatment of rabbits for 14 days with the thiamin antagonists pyrithiamin (20 μg kg-1) or oxythiamin (0.8 mg kg-1) produced a significant drop in TK activity and increase in the lactate and pyruvate concentrations as well as an increase in TPP effect. Pyrithiamin (5, 10 or 20 μg kg-1, 14 days) lowered siginficantly the activity of MAO in the liver and brain of rabbits. Treatment with the other antagonist, oxythiamin, at doses of 0.2 or 0.4 mg kg-1 for 14 days had no significant effect on MAO activity. At a dose of 0.8 mg kg-1 a significant drop in MAO activity occurred. A pair-feeding trial indicated that the biochemical changes produced in animals treated with MAO inhibitors were attributable to the drugs per se, and not to the ensuing anorexia. Thiamin (100 μg kg-1, subcutaneously) when given concomitantly with pyrithiamin, oxythiamin, harmaline, deprenyl and tranylcypromine was effective in preventing the development of thiamin deficiency.

Original languageEnglish
Pages (from-to)869-875
Number of pages7
JournalBritish Journal of Pharmacology
Volume86
Issue number4
Publication statusPublished - 1985

Fingerprint

Monoamine Oxidase Inhibitors
Thiamine
Oxythiamine
Oxidoreductases
Pyrithiamine
Transketolase
Thiamine Pyrophosphate
Rabbits
Harmaline
Iproniazid
Pyruvic Acid
Clorgyline
Tranylcypromine
Selegiline
Lactic Acid
Anorexia
Erythrocytes
Thiamine Deficiency
Pharmaceutical Preparations
Body Weight

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effect of some monoamine oxidase inhibitors on the thiamin status of rabbits. / Ali, B. H.

In: British Journal of Pharmacology, Vol. 86, No. 4, 1985, p. 869-875.

Research output: Contribution to journalArticle

@article{2686fb25e2cd4e5582cc59599e948171,
title = "Effect of some monoamine oxidase inhibitors on the thiamin status of rabbits",
abstract = "The monamine oxidase (MAO) inhibitors harmaline, tranylcypromine, deprenyl, clorgyline and iproniazid were injected intraperitoneally for five days to rabbits at doses that produced significant MAO inhibition. The first three inhibitors raised the concentrations of pyruvate and lactate in blood, decreased the activity of erythrocyte transketolase (TK) and increased the thiamin pyrophosphate (TPP) effect. The drugs also produced anorexia and loss of body weight. The changes were suggestive of an adverse effect on the thiamin status. Clorgyline and iproniazid, however, raised the blood concentrations of pyruvate and lactate but did not affect significantly erythrocyte TK activity or TPP effect. Treatment of rabbits for 14 days with the thiamin antagonists pyrithiamin (20 μg kg-1) or oxythiamin (0.8 mg kg-1) produced a significant drop in TK activity and increase in the lactate and pyruvate concentrations as well as an increase in TPP effect. Pyrithiamin (5, 10 or 20 μg kg-1, 14 days) lowered siginficantly the activity of MAO in the liver and brain of rabbits. Treatment with the other antagonist, oxythiamin, at doses of 0.2 or 0.4 mg kg-1 for 14 days had no significant effect on MAO activity. At a dose of 0.8 mg kg-1 a significant drop in MAO activity occurred. A pair-feeding trial indicated that the biochemical changes produced in animals treated with MAO inhibitors were attributable to the drugs per se, and not to the ensuing anorexia. Thiamin (100 μg kg-1, subcutaneously) when given concomitantly with pyrithiamin, oxythiamin, harmaline, deprenyl and tranylcypromine was effective in preventing the development of thiamin deficiency.",
author = "Ali, {B. H.}",
year = "1985",
language = "English",
volume = "86",
pages = "869--875",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Effect of some monoamine oxidase inhibitors on the thiamin status of rabbits

AU - Ali, B. H.

PY - 1985

Y1 - 1985

N2 - The monamine oxidase (MAO) inhibitors harmaline, tranylcypromine, deprenyl, clorgyline and iproniazid were injected intraperitoneally for five days to rabbits at doses that produced significant MAO inhibition. The first three inhibitors raised the concentrations of pyruvate and lactate in blood, decreased the activity of erythrocyte transketolase (TK) and increased the thiamin pyrophosphate (TPP) effect. The drugs also produced anorexia and loss of body weight. The changes were suggestive of an adverse effect on the thiamin status. Clorgyline and iproniazid, however, raised the blood concentrations of pyruvate and lactate but did not affect significantly erythrocyte TK activity or TPP effect. Treatment of rabbits for 14 days with the thiamin antagonists pyrithiamin (20 μg kg-1) or oxythiamin (0.8 mg kg-1) produced a significant drop in TK activity and increase in the lactate and pyruvate concentrations as well as an increase in TPP effect. Pyrithiamin (5, 10 or 20 μg kg-1, 14 days) lowered siginficantly the activity of MAO in the liver and brain of rabbits. Treatment with the other antagonist, oxythiamin, at doses of 0.2 or 0.4 mg kg-1 for 14 days had no significant effect on MAO activity. At a dose of 0.8 mg kg-1 a significant drop in MAO activity occurred. A pair-feeding trial indicated that the biochemical changes produced in animals treated with MAO inhibitors were attributable to the drugs per se, and not to the ensuing anorexia. Thiamin (100 μg kg-1, subcutaneously) when given concomitantly with pyrithiamin, oxythiamin, harmaline, deprenyl and tranylcypromine was effective in preventing the development of thiamin deficiency.

AB - The monamine oxidase (MAO) inhibitors harmaline, tranylcypromine, deprenyl, clorgyline and iproniazid were injected intraperitoneally for five days to rabbits at doses that produced significant MAO inhibition. The first three inhibitors raised the concentrations of pyruvate and lactate in blood, decreased the activity of erythrocyte transketolase (TK) and increased the thiamin pyrophosphate (TPP) effect. The drugs also produced anorexia and loss of body weight. The changes were suggestive of an adverse effect on the thiamin status. Clorgyline and iproniazid, however, raised the blood concentrations of pyruvate and lactate but did not affect significantly erythrocyte TK activity or TPP effect. Treatment of rabbits for 14 days with the thiamin antagonists pyrithiamin (20 μg kg-1) or oxythiamin (0.8 mg kg-1) produced a significant drop in TK activity and increase in the lactate and pyruvate concentrations as well as an increase in TPP effect. Pyrithiamin (5, 10 or 20 μg kg-1, 14 days) lowered siginficantly the activity of MAO in the liver and brain of rabbits. Treatment with the other antagonist, oxythiamin, at doses of 0.2 or 0.4 mg kg-1 for 14 days had no significant effect on MAO activity. At a dose of 0.8 mg kg-1 a significant drop in MAO activity occurred. A pair-feeding trial indicated that the biochemical changes produced in animals treated with MAO inhibitors were attributable to the drugs per se, and not to the ensuing anorexia. Thiamin (100 μg kg-1, subcutaneously) when given concomitantly with pyrithiamin, oxythiamin, harmaline, deprenyl and tranylcypromine was effective in preventing the development of thiamin deficiency.

UR - http://www.scopus.com/inward/record.url?scp=0022382242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022382242&partnerID=8YFLogxK

M3 - Article

C2 - 4075020

AN - SCOPUS:0022382242

VL - 86

SP - 869

EP - 875

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 4

ER -